Back to top
more

AngioDynamics (ANGO)

(Delayed Data from NSDQ)

$6.37 USD

6.37
2,238,320

-1.28 (-16.73%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $6.58 +0.21 (3.30%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (59 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Surmodics (SRDX) Reports Q4 Loss, Revenues Beat Estimates

Surmodics (SRDX) registered revenue decline in each of its core units in the fourth quarter.

Pacific Biosciences (PACB) Loses 4.1% Post Reporting Q3 Loss

Pacific Biosciences (PACB) saw revenue decline in both its operating segments in the third quarter.

Avanos Medical (AVNS) Q3 Earnings and Revenues Top Estimates

Avanos Medical (AVNS) continued to gain from core Chronic Care segment in the third quarter.

McKesson (MCK) Q2 Earnings and Revenues Surpass Estimates

McKesson's (MCK) fiscal second-quarter 2021 results benefit from strong segmental performance.

Accuray (ARAY) Climbs 11.5% as Q1 Earnings Beat Estimates

Accuray (ARAY) registered growth in Service revenues in Q1.

OPKO Health (OPK) Loses 16.2% Despite In-Line Q3 Earnings

OPKO Health's (OPK) third-quarter results benefit from increase in RAYALDEE prescriptions.

Allscripts (MDRX) Declines 1.9% Despite Q3 Earnings Beat

Allscripts (MDRX) witnessed decline in core Client Services and Software delivery unit revenues during the third quarter.

Integer Holdings (ITGR) Q3 Earnings Beat Estimates, Down Y/Y

Integer Holdings' (ITGR) third-quarter results reflect weak segmental performance.

Stryker (SYK) Q3 Earnings and Revenues Surpass Estimates

Stryker's (SYK) third-quarter earnings reflect strong segmental performance.

Merit Medical (MMSI) Rallies 4.8% Post Q3 Earnings Beat

Merit Medical (MMSI) reported growth in revenues at Cardiovascular segment in the third quarter.

DaVita (DVA) Earnings Beat Estimates in Q3, Revenues Miss

DaVita (DVA) saw strength in dialysis services in the United States in the third quarter.

Omnicell (OMCL) Q3 Earnings Top, Pre-COVID-19 View Reinstated

Omnicell's (OMCL) Service and other revenues improve in Q3 despite the pandemic-led business challenges.

AngioDynamics (ANGO) Down 12.1% Since Last Earnings Report: Can It Rebound?

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Globus Medical (GMED) Q3 Earnings Beat, U.S. Business Strong

Globus Medical's (GMED) spinal implant business performance varies by region in Q3.

Baxter (BAX) Q3 Earnings and Revenues Surpass Estimates

Baxter's (BAX) third-quarter results reflect strong performance across six of its business units.

ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q2

ABIOMED's (ABMD) international Impella revenues improved in Q2.

CONMED (CNMD) Earnings and Revenues Surpass Estimates in Q3

CONMED's (CNMD) General Surgery unit witnessed revenue growth in Q3

Cerner (CERN) Q3 Earnings Surpass Estimates, Revenues Miss

Cerner's (CERN) third-quarter results benefit from gains in Licensed software, Subscriptions and Managed services units, and expansion in margins.

PerkinElmer (PKI) Q3 Earnings and Revenues Surpass Estimates

PerkinElmer's (PKI) third-quarter results benefit from growth in Diagnostics segment. However, forex remains a woe.

AngioDynamics (ANGO) Upgraded to Strong Buy: What Does It Mean for the Stock?

AngioDynamics (ANGO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Here's Why You Should Add AngioDynamics to Your Portfolio Now

Investor confidence is high in AngioDynamics (ANGO) stock, thanks to solid prospects.

AngioDynamics' Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in AngioDynamics.

AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates

AngioDynamics (ANGO) witnessed revenue growth across two business segments in fiscal Q1.

AngioDynamics (ANGO) in Focus: Stock Moves 6.2% Higher

AngioDynamics (ANGO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

AngioDynamics (ANGO) Tops Q1 Earnings and Revenue Estimates

AngioDynamics (ANGO) delivered earnings and revenue surprises of 133.33% and 6.95%, respectively, for the quarter ended August 2020. Do the numbers hold clues to what lies ahead for the stock?